Boardroom Alpha
Start trial
10-K primary document
NVCR · Annual Report (Form 10-K) · Filed February 26, 2026

Novocure Ltd — 10-K exhibit

nvcr-20251231x10kex231.htm
Novocure Ltd on Boardroom Alpha
Document
Ex 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:
(1)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-209854) pertaining to the NovoCure Limited Employee Share Purchase Plan, the NovoCure Limited 2015 Omnibus Incentive Plan, the NovoCure Limited 2013 Share Option Plan, the Standen Limited 2003 Share Option Plan and NovoCure Limited 2024 Omnibus Incentive Plan,
(2)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-217619) pertaining to the NovoCure Limited Employee Share Purchase Plan, the NovoCure Limited 2015 Omnibus Incentive Plan and NovoCure Limited 2024 Omnibus Incentive Plan,
(3)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-224606) pertaining to the NovoCure Limited 2015 Omnibus Incentive Plan, NovoCure Limited 2024 Omnibus Incentive Plan,
(4)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-232896) pertaining to the NovoCure Limited Employee Share Purchase Plan, the NovoCure Limited 2015 Omnibus Incentive Plan and NovoCure Limited 2024 Omnibus Incentive Plan,
(5)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-236862) pertaining to the NovoCure Limited Employee Share Purchase Plan, the NovoCure Limited 2015 Omnibus Incentive Plan and NovoCure Limited 2024 Omnibus Incentive Plan,
(6)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-253499) pertaining to the NovoCure Limited Employee Share Purchase Plan, the NovoCure Limited 2015 Omnibus Incentive Plan and NovoCure Limited 2024 Omnibus Incentive Plan,
(7)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-262965) pertaining to the NovoCure Limited 2015 Omnibus Incentive Plan and NovoCure Limited 2024 Omnibus Incentive Plan,
(8)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333-269926) pertaining to the NovoCure Limited 2015 Omnibus Incentive Plan and NovoCure Limited 2024 Omnibus Incentive Plan,
(9)Post Effective Amendment no. 1 to the Registration Statement (Form S-8 No. 333- 277240) pertaining to the NovoCure Limited 2015 Omnibus Incentive Plan, NovoCure Limited Employee Share Purchase Plan and NovoCure Limited 2024 Omnibus Incentive Plan, and

(10) Post Effective Amendment no. 2 to the Registration Statement (Form S-8 No. 333-285300) pertaining to the NovoCure Limited Employee Share Purchase Plan, the NovoCure Limited 2015 Omnibus Incentive Plan and NovoCure Limited 2024 Omnibus Incentive Plan.

of our reports dated February 26, 2026, with respect to the consolidated financial statements of NovoCure Limited and the effectiveness of internal control over financial reporting of NovoCure Limited included in this Annual Report (Form 10-K) of NovoCure Limited for the year ended December 31, 2025.
 

Ex 23.1
/s/KOST FORER GABBAY AND KASIERER
A member of EY Global
Tel Aviv, Israel
 

February 26, 2026
 



Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer